These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29870139)

  • 21. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thalidomide, cereblon and multiple myeloma].
    Ogura T
    Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
    Ito T; Handa H
    Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
    Gooding S; Ansari-Pour N; Towfic F; Ortiz Estévez M; Chamberlain PP; Tsai KT; Flynt E; Hirst M; Rozelle D; Dhiman P; Neri P; Ramasamy K; Bahlis N; Vyas P; Thakurta A
    Blood; 2021 Jan; 137(2):232-237. PubMed ID: 33443552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cereblon as a primary target of IMiDs].
    Ito T; Handa H
    Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
    Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
    Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
    Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
    Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
    Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
    J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory drugs in the treatment of multiple myeloma.
    Abe Y; Ishida T
    Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunomodulatory drugs (IMiDs)].
    Oshima K; Ichinohe T
    Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.
    Charliński G; Vesole DH; Jurczyszyn A
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors.
    Kowalski TW; Feira MF; Lord VO; Gomes JDA; Giudicelli GC; Fraga LR; Sanseverino MTV; Recamonde-Mendoza M; Schuler-Faccini L; Vianna FSL
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
    Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
    Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
    Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
    Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
    Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
    Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
    Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
    Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cereblon -  a new target of therapy in the treatment of multiple myeloma].
    Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.